Document is current
Any future updates will be listed below
-
Authors
Hrovatin, Karin https://orcid.org/0000-0003-3319-9645
Sikkema, Lisa https://orcid.org/0000-0001-9686-6295
Shitov, Vladimir A. https://orcid.org/0000-0002-1960-8812
Heimberg, Graham
Shulman, Maiia https://orcid.org/0009-0006-6308-1997
Oliver, Amanda J.
Mueller, Michaela F.
Ibarra, Ignacio L. https://orcid.org/0000-0002-0582-002X
Wang, Hanchen https://orcid.org/0000-0002-1691-024X
Ramírez-Suástegui, Ciro
He, Peng https://orcid.org/0000-0002-2457-3554
Schaar, Anna C.
Teichmann, Sarah A. https://orcid.org/0000-0002-6294-6366
Theis, Fabian J. https://orcid.org/0000-0002-2419-1943
Luecken, Malte D. https://orcid.org/0000-0001-7464-7921
- License Information
-
More Information
Article History
Received: 31 October 2023
Accepted: 22 October 2024
First Online: 13 December 2024
Competing interests
: G.H. and H.W. are employees of Genentech whose views are their own and do not represent those of Genentech, Roche or affiliates. M.D.L. contracted for the Chan Zuckerberg Initiative, consults for CatalYm and received speaker fees from Pfizer and Janssen Pharmaceuticals. S.A.T. has consulted for or been a member of scientific advisory boards at Qiagen, Sanofi, GlaxoSmithKline and ForeSite Labs. S.A.T. is a cofounder and an equity holder of TransitionBio and EnsoCell and a SAB member of Element Biosciences and an independent non-executive director on the 10X Genomics board. S.A.T. is a part-time employee at GlaxoSmithKline. F.J.T. consults for Immunai, Singularity Bio B.V., CytoReason, Cellarity and Curie Bio Operations and has an ownership interest in Dermagnostix and Cellarity. The remaining authors declare no competing interests.
